The impact of antigenic drift of influenza A virus on human herd immunity: Sero-epidemiological study of H1N1 in healthy Thai population in 2009

Vaccine

Volumn 28, Issue 33, 2010, Pages 5437-5444

  Kanai, Yuta ^a   Boonsathorn, Naphatsawan ^b   Chittaganpitch, Malinee ^c   Bai, Guirong ^a   Li, Yonggang ^a   Kase, Tetsuo ^d   Takahashi, Kazuo ^d   Okuno, Yoshinobu ^e   Jampangern, Wipawee ^a   Ikuta, Kazuyoshi ^a,f   Sawanpanyalert, Pathom ^c  

^a Thailand Japan Research Collaboration Center on Emerging and Re emerging Infections RCC ERI   (Thailand)

^b Medical Biotechnology Center   (Thailand)

^c NATIONAL INSTITUTES OF HEALTH   (United States)

^d OSAKA PREFECTURAL INSTITUTE OF PUBLIC HEALTH   (Japan)

^e Osaka University   (Japan)

^f OSAKA UNIVERSITY   (Japan)

Author keywords

Antibody; Epidemiology; Thailand

Indexed keywords

AMINO ACID; NEUTRALIZING ANTIBODY;

AMINO ACID SEQUENCE; ANTIBODY DETECTION; ANTIBODY TITER; ANTIGENICITY; ARTICLE; BLOOD SAMPLING; CELL STRAIN; HEMAGGLUTINATION INHIBITION TEST; HERD IMMUNITY; HUMAN; IMMUNOHISTOCHEMISTRY; INFLUENZA; INFLUENZA VIRUS A H1N1; NORMAL HUMAN; NUCLEOTIDE SEQUENCE; PHYLOGENETIC TREE; PRIORITY JOURNAL; SEROEPIDEMIOLOGY; THAILAND; VIRUS ISOLATION;

ANTIGENS, VIRAL; ASIAN CONTINENTAL ANCESTRY GROUP; FEMALE; HUMANS; IMMUNITY, HERD; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA VACCINES; INFLUENZA, HUMAN; MALE; SEROEPIDEMIOLOGIC STUDIES; THAILAND;

EID: 77955086950     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2010.06.002     Document Type: Article

References (40)

1. Yu X., Tsibane T., McGraw P.A., House F.S., Keefer C.J., Hicar M.D., et al. Neutralizing antibodies derived from the B cells of 1918 influenza pandemic survivors. Nature 2008, 455(7212):532-536.
2. Smith D.J., Lapedes A.S., de Jong J.C., Bestebroer T.M., Rimmelzwaan G.F., Osterhaus A.D., et al. Mapping the antigenic and genetic evolution of influenza virus. Science 2004, 305(5682):371-376.
3. Plotkin J.B., Dushoff J., Levin S.A. Hemagglutinin sequence clusters and the antigenic evolution of influenza A virus. Proc Natl Acad Sci USA 2002, 99(9):6263-6268.
4. Koelle K., Cobey S., Grenfell B., Pascual M. Epochal evolution shapes the phylodynamics of interpandemic influenza A (H3N2) in humans. Science 2006, 314(5807):1898-1903.
5. Carrat F., Flahault A. Influenza vaccine: the challenge of antigenic drift. Vaccine 2007, 25(39-40):6852-6862.
6. Kilbourne E.D., Smith C., Brett I., Pokorny B.A., Johansson B., Cox N. The total influenza vaccine failure of 1947 revisited: major intrasubtypic antigenic change can explain failure of vaccine in a post-World War II epidemic. Proc Natl Acad Sci USA 2002, 99(16):10748-10752.
7. Layne S.P. Human influenza surveillance: the demand to expand. Emerg Infect Dis 2006, 12(4):562-568.
8. Rambaut A., Pybus O.G., Nelson M.I., Viboud C., Taubenberger J.K., Holmes E.C. The genomic and epidemiological dynamics of human influenza A virus. Nature 2008, 453(7195):615-619.
9. World Health Organization Wkly Epidemiol Rec 2007, 82:69-76.
10. Treanor J. Influenza vaccine-outmaneuvering antigenic shift and drift. N Engl J Med 2004, 350(3):218-220.
11. Russell C.A., Jones T.C., Barr I.G., Cox N.J., Garten R.J., Gregory V., et al. The global circulation of seasonal influenza A (H3N2) viruses. Science 2008, 320(5874):340-346.
12. Viboud C., Alonso W.J., Simonsen L. Influenza in tropical regions. PLoS Med 2006, 3(4):e89.
13. Bai G.R., Chittaganpitch M., Kanai Y., Li Y.G., Auwanit W., Ikuta K., et al. Amantadine- and oseltamivir-resistant variants of influenza A viruses in Thailand. Biochem Biophys Res Commun 2009, 390(3):897-901.
14. Okuno Y., Tanaka K., Baba K., Maeda A., Kunita N., Ueda S. Rapid focus reduction neutralization test of influenza A and B viruses in microtiter system. J Clin Microbiol 1990, 28(6):1308-1313.
15. Hoffmann E., Stech J., Guan Y., Webster R.G., Perez D.R. Universal primer set for the full-length amplification of all influenza A viruses. Arch Virol 2001, 146(12):2275-2289.
16. Tamura K., Dudley J., Nei M., Kumar S., MEGA4: Molecular Evolutionary Genetics Analysis (MEGA) software version 4.0. Mol Biol Evol 2007, 24(8):1596-1599.
17. Okuno Y., Isegawa Y., Sasao F., Ueda S. A common neutralizing epitope conserved between the hemagglutinins of influenza A virus H1 and H2 strains. J Virol 1993, 67(5):2552-2558.
18. Caton A.J., Brownlee G.G., Yewdell J.W., Gerhard W. The antigenic structure of the influenza virus A/PR/8/34 hemagglutinin (H1 subtype). Cell 1982, 31(2 Pt 1):417-427.
19. Brownlee G.G., Fodor E. The predicted antigenicity of the haemagglutinin of the 1918 Spanish influenza pandemic suggests an avian origin. Philos Trans R Soc Lond B: Biol Sci 2001, 356(1416):1871-1876.
20. Igarashi M., Ito K., Yoshida R., Tomabechi D., Kida H., Takada A. Predicting the antigenic structure of the pandemic (H1N1) 2009 influenza virus hemagglutinin. PLoS One 2010, 5(1):e8553.
21. Simmerman J.M., Chittaganpitch M., Levy J., Chantra S., Maloney S., Uyeki T., et al. Incidence, seasonality and mortality associated with influenza pneumonia in Thailand: 2005-2008. PLoS One 2009, 4(11):e7776.
22. Harmon M.W., Rota P.A., Walls H.H., Kendal A.P. Antibody response in humans to influenza virus type B host-cell-derived variants after vaccination with standard (egg-derived) vaccine or natural infection. J Clin Microbiol 1988, 26(2):333-337.
23. Zakay-Rones Z., Margalith E., Levy R., Katz E. A sensitive plaque inhibition technique for assay of antibodies to influenza virus: use to detect previous antigenic priming with influenza viruses. J Virol Methods 1980, 1(6):355-360.
24. Rowe T., Abernathy R.A., Hu-Primmer J., Thompson W.W., Lu X., Lim W., et al. Detection of antibody to avian influenza A (H5N1) virus in human serum by using a combination of serologic assays. J Clin Microbiol 1999, 37(4):937-943.
25. Sukeno N., Otsuki Y., Konno J., Yamane N., Odagiri T., Arikawa J., et al. Anti-nucleoprotein antibody response in influenza A infection. Tohoku J Exp Med 1979, 128(3):241-249.
26. Rangel-Moreno J., Carragher D.M., Misra R.S., Kusser K., Hartson L., Moquin A., et al. B cells promote resistance to heterosubtypic strains of influenza via multiple mechanisms. J Immunol 2008, 180(1):454-463.
27. Stephenson I., Das R.G., Wood J.M., Katz J.M. Comparison of neutralising antibody assays for detection of antibody to influenza A/H3N2 viruses: an international collaborative study. Vaccine 2007, 25(20):4056-4063.
28. Hilleman M.R. Realities and enigmas of human viral influenza: pathogenesis, epidemiology and control. Vaccine 2002, 20(25-26):3068-3087.
29. Ndifon W., Wingreen N.S., Levin S.A. Differential neutralization efficiency of hemagglutinin epitopes, antibody interference, and the design of influenza vaccines. Proc Natl Acad Sci USA 2009, 106(21):8701-8706.
30. Wiley D.C., Wilson I.A., Skehel J.J. Structural identification of the antibody-binding sites of Hong Kong influenza haemagglutinin and their involvement in antigenic variation. Nature 1981, 289(5796):373-378.
31. Wilson I.A., Niman H.L., Houghten R.A., Cherenson A.R., Connolly M.L., Lerner R.A. The structure of an antigenic determinant in a protein. Cell 1984, 37(3):767-778.
32. Green N., Alexander H., Olson A., Alexander S., Shinnick T.M., Sutcliffe J.G., et al. Immunogenic structure of the influenza virus hemagglutinin. Cell 1982, 28(3):477-487.
33. Nelson M.I., Edelman L., Spiro D.J., Boyne A.R., Bera J., Halpin R., et al. Molecular epidemiology of A/H3N2 and A/H1N1 influenza virus during a single epidemic season in the United States. PLoS Pathog 2008, 4(8):e1000133.
34. Hsieh Y.C., Chen H.Y., Yen J.J., Liu D.P., Chang L.Y., Lu C.Y., et al. Influenza in Taiwan: seasonality and vaccine strain match. J Microbiol Immunol Infect 2005, 38(4):238-243.
35. Simmons C.P., Bernasconi N.L., Suguitan A.L., Mills K., Ward J.M., Chau N.V., et al. Prophylactic and therapeutic efficacy of human monoclonal antibodies against H5N1 influenza. PLoS Med 2007, 4(5):e178.
36. Carragher D.M., Kaminski D.A., Moquin A., Hartson L., Randall T.D. A novel role for non-neutralizing antibodies against nucleoprotein in facilitating resistance to influenza virus. J Immunol 2008, 181(6):4168-4176.
37. Mozdzanowska K., Feng J., Eid M., Zharikova D., Gerhard W. Enhancement of neutralizing activity of influenza virus-specific antibodies by serum components. Virology 2006, 352(2):418-426.
38. Feng J.Q., Mozdzanowska K., Gerhard W. Complement component C1q enhances the biological activity of influenza virus hemagglutinin-specific antibodies depending on their fine antigen specificity and heavy-chain isotype. J Virol 2002, 76(3):1369-1378.
39. Zheng B., Zhang Y., He H., Marinova E., Switzer K., Wansley D., et al. Rectification of age-associated deficiency in cytotoxic T cell response to influenza A virus by immunization with immune complexes. J Immunol 2007, 179(9):6153-6159.
40. Peiris J.S., de Jong M.D., Guan Y. Avian influenza virus (H5N1): a threat to human health. Clin Microbiol Rev 2007, 20(2):243-267.